Your browser doesn't support javascript.
loading
The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.
Afzalipour, Reza; Abbasi-Dokht, Tannaz; Sheikh, Maryam; Mohammadlou, Maryam; Nili, Fatemeh; Baharlou, Rasoul.
Afiliación
  • Afzalipour R; Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
  • Abbasi-Dokht T; Department of Radiology, Faculty of Para-Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
  • Sheikh M; Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Mohammadlou M; Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
  • Nili F; Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Baharlou R; Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
J Gastrointest Cancer ; 55(3): 1380-1387, 2024 Sep.
Article en En | MEDLINE | ID: mdl-39046662
ABSTRACT

BACKGROUND:

Angiogenesis and cancer metastasis depend on the DLL4/Notch signaling pathway. A new approach to treating angiogenesis could inhibit or block this pathway. In the present study, we investigated DLL4 expression as a biomarker capable of predicting survival outcomes in gastric cancer patients using a novel anti-DLL4 Nanobody. PATIENTS AND

METHODS:

By using a recently developed anti-DLL4 Nanobody, the expression of DLL4 was evaluated in tissue samples from 135 gastric cancer patients. It was evaluated whether DLL4 expression is related to clinicopathological factors, overall survival (OS), and recurrence-free survival (RFS).

RESULTS:

Sixty-five (48%) gastric cancer patients had a positive expression of DLL4 within the tumor tissue. Based on both the univariate and multivariate regression analyses, the expression of DLL4 was strongly associated with RFS (HR, 1.94; p = 0.008) and OS (HR, 2.06; p = 0.004). Moreover, the survival analysis demonstrated that DLL4 expression was a significant independent factor of unfavorable OS (HR, 2.7; p = 0.01) and RFS (HR, 2.3; p = 0.02) in gastric cancer patients.

CONCLUSION:

DLL4 expression in gastric cancer patients may predict poor prognosis and survival. Furthermore, the current data demonstrate the potential of Nanobody for detecting DLL4, and it may lead to develop novel therapies and diagnostics for tumors.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Proteínas de Unión al Calcio / Biomarcadores de Tumor / Proteínas Adaptadoras Transductoras de Señales Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Proteínas de Unión al Calcio / Biomarcadores de Tumor / Proteínas Adaptadoras Transductoras de Señales Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Gastrointest Cancer Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos